Long-term safety, tolerability, and efficacy of OROS® hydromorphone in patients with chronic pain

Journal of Opioid Management

Volumn 5, Issue 2, 2009, Pages 97-105

  Wallace, Mark ^a   Moulin, Dwight E ^b   Rauck, Richard L ^c   Khanna, Sarita ^d   Tudor, Iulia Cristina ^d   Skowronski, Roman ^d   Thipphawong, John ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d ALZA CORPORATION   (United States)

Author keywords

Chronic pain; Efficacy; Hydromorphone; Long term management; Safety; Tolerability

Indexed keywords

HYDROMORPHONE; NARCOTIC ANALGESIC AGENT; OROS; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERHIDROSIS; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; VOMITING;

EID: 65749098996     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0011     Document Type: Article

References (18)

1. Harstall C, Ospina M: How prevalent is chronic pain? Pain: Clinical Updates. 2003; XI(2): 1-4.
2. Breivik H, Collett B, Ventafridda V, et al.: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10(4): 287-333.
3. Chronic pain in America: Roadblocks to relief, 1999. Available at: www.ampainsoc.org/links/roadblocks/. Accessed May 31, 2006.
4. Lazarus H, Neumann CJ: Assessing undertreatment of pain: The patients' perspectives. J Pharm Care Pain Symptom Control. 2001; 9(4): 5-34.
5. Croft PR, Macfarlane GJ, Papageorgiou AC, et al.: Outcome of low back pain in general practice: A prospective study. BMJ. 1998; 316(7141): 1356-1359.
6. Angst MS, Drover DR, Lotsch J, et al.: Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology. 2001; 94(1): 63-73.
7. Drover DR, Angst MS, Valle M, et al.: Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002; 97(4): 827-836.
8. Hale M, Tudor IC, Khanna S, et al.: Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007; 29(5): 874-888.
9. Wallace M, Rauck RL, Moulin D, et al.: Conversion from standard opioid therapy to once-daily oral, extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res. 2007; 36(2): 343-352.
10. Wallace M, Rauck RL, Moulin D, et al.: Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: A dose-conversion and titration study. Int J Clin Pract. 2007; 61(10): 1671-1676.
11. Daut RL, Cleeland CS, Flanery RC: Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983; 17(2): 197-210.
12. Eisenberg E, McNicol ED, Carr DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta analysis of randomized controlled trials. JAMA. 2005; 293(24): 3043-3052.
13. Roth SH, Fleischmann RM, Burch FX, et al.: Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: Placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000; 160(6): 853-860.
14. McIlwain H, Ahdieh H: Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study. Am J Ther. 2005; 12(2): 106-112.
15. Allan L, Richarz U, Simpson K, et al.: Transdermal fentanyl versus sustained-release oral morphine in strong-opioid naive patients with chronic low back pain. Spine. 2005; 30(22): 2484-2490.
16. Mitra S: Opioid-induced hyperalgesia: Pathophysiology and clinical implications. J Opioid Manag. 2008; 4(3): 123-130.
17. Chu LF, Angst MS, Clark D: Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008; 24(6):479-496.
18. Cherny N: New strategies in opioid therapy for cancer pain. J Oncol Manag. 2000; 9(1): 8-15.